UKUlyana Gordeevna Koshkina

Ulyana Gordeevna Koshkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ulyana Gordeevna Koshkina has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Primary Central Nervous System Lymphoma: A Literature Review, Diagnosis, Treatment, and Prognosis

    by Selmi Faikovna Ramazanova, A. V. Arakelyan, A. A. Semenova, O. Yu. Baranova, D. N. Tupitsyna, M. Yu. Kichigina, O. P. Trofimova, G. D. Petrova, A. S. Subbotin, V. O. Shpirko, et al.

    BACKGROUND. Primary lymphoma of the CNS (PLCNS) is one of the rare extranodal lymphoid tumors, which, in the vast majority of cases, is represented by diffuse large B-cell lymphoma (DLBCL). Tumor location, poor performance status with frequent neurological deficits as well as elderly age of the majority of patients restrict the opportunities for both diagnosis and treatment of this disease. AIM. To study the clinical manifestations and chemotherapy options for patients with newly diagnosed PLCNS. MATERIALS & METHODS. This study was based on the clinical data from 29 PLCNS patients treated at the Drug Chemotherapy and Hematology Department of the NN Blokhin National Medical Cancer Research Center from 2020 to 2025. The median age was 57 years (range 34–71 years), 35 % of patients were over 60 years of age, there were 16 (55 %) men. On presentation, more than a half of patients (n = 18; 62 %) had poor performance status (ECOG > 2). By immunohistochemical analysis, DLBCL was diagnosed in all patients: in 22 cases stereotactic biopsy was performed to verify the diagnosis, whereas in 7 cases open surgery was needed. An absolute majority of patients (n = 26; 90 %) received high-dose methotrexate (3–3.5 g/m2) as part of various combined regimens: R-MVT in 19 (66 %), R-MVР in 2 (7 %), R2-MV in 4 (14 %), and R-МAra-C in 1 (3 %) cases. Those 14 (48 %) patients who achieved antitumor effect after 2–4 cycles underwent consolidation in the form of external beam radiation therapy (n = 6; 21 %) or high-dose chemotherapy (n = 8; 28 %) with autologous hematopoietic stem cell transplantation (auto-HSCT). Maintenance therapy with temozolomide or lenalidomide was administered to 10 (35 %) patients. RESULTS. With the median follow-up of 13 months, the 2-year progression-free survival (PFS) was 34.5 % (median 9 months), and the 2-year overall survival (OS) was 54.3 % (median 35 months). The most important prognostic factor was achievement of complete remission (CR): the median PFS in patients with CR was 17 months vs. 2 months in patients without it, the median OS was 35 months and 5 months, respectively. Consolidation therapy, regardless of the method used (radiation therapy or auto-HSCT), also considerably improved the rates of long-term survival: the 2-year PFS was 55.1 % vs. 9.7 % without consolidation, the 2-year OS was 79.5 % and 30.5 %, respectively. CONCLUSION. PLCNS is characterized by a highly aggressive course. Administration of methotrexate-based regimens combined with alkylating or immunomodulatory agents followed by consolidation therapy is associated with improved rates of long-term survival. The results of first-line therapy present a key factor in determining the outcome of the disease, since the available treatment options for relapsed/refractory tumors of this kind are extremely limited and hardly effective.

  • Open Access

    Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: A Literature Review and Our Own Experience

    by Ulyana Gordeevna Koshkina, A. A. Semenova, M. Yu. Kichigina, D. N. Tupitsyna, V. O. Shpirko, A. I. Cherencova, S. F. Ramazanova, N. O. Zemlyakov, I. Z. Zavodnova, A. V. Arakelyan, et al.

    AIM. To assess the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKi) as first and subsequent lines of mantle cell lymphoma (MCL) therapy. MATERIALS & METHODS. This study enrolled 30 patients with newly diagnosed (ndMCL; n = 17) and relapsed/refractory MCL (r/r MCL; n = 13) treated with BTKi at the Drug Chemotherapy and Hematology Department of the NN Blokhin National Medical Cancer Research Center during 2016–2025. NdMCL patients less than 60 years of age (n = 10/17; 58 %) were treated with alternating regimen R-CHOP + I/R-DHAOx combined with BTKi, 6 of them received high-dose chemotherapy with autologous hematopoietic stem cell transplantation. Elderly ndMCL patients (n = 7/17; 41 %) were treated with R-B program combined with BTKi. Irrespective of the induction phase, rituximab maintenance therapy (3 years) and BTKi (2 years) were administered to all patients. For the treatment of r/r MCL, BTKi was used as a monoregimen in 6 (46 %) patients, 2 (15 %) patients received it in combination with R-B, and 5 (38 %) in combination with rituximab. RESULTS. With the median follow-up of 36 months, ndMCL patients (n = 17) showed the 3-year progression-free survival (PFS) of 81.4 % and the 3-year overall survival (OS) of 84.4 %. In the r/r MCL group, with the median follow-up of 22 months, the 3-year PFS was 60.9 %, and the 3-year OS was 67 %. During this time, in the period from 3 to 23 months, 3 patients died (2 of them due to disease progression and 1 died from an infection). Toxicity profile of BTKi combination appeared to be manageable, whereas more infectious complications (53.8 % vs. 35.3 %) and more cases of pneumonia (53.8 vs. 29.4 %) were observed in r/r MCL vs. ndMCL patients. CONCLUSION. The administration of BTKi combined with chemotherapy is associated with high efficacy and favorable toxicity profile in the treatment of both ndMCL and r/r MCL.

  • Open Access

    The Prognostic Value of Positron Emission Tomography Findings in the Treatment of Primary Mediastinal (Thymic) Large B-Cell Lymphoma

    by A. S. Subbotin, Arman Vachakanovich Arakelyan, G. S. Tumyan, V. V. Solomyanyi, B. M. Khakulova, A. A. Semenova, M. Yu. Kichigina, I. Z. Zavodnova, V. O. Shpirko, Yu. I. Klyuchagina, et al.

    BACKGROUND. Combined positron emission tomography/computed tomography (PET-CT) with [18F]fluorodeoxyglucose is an essential instrument of monitoring the response to chemotherapy in primary mediastinal (thymic) large B-cell lymphoma (PMBCL). Of outstanding interest is the interpretation of PET-CT findings with respect to the frequent persistence of large residual mediastinal tumor after the end of drug therapy in PMBCL patients. AIM. To assess the prognostic value of PET-CT findings at different treatment stages in patients with newly diagnosed PMBCL. MATERIALS & METHODS. This study is based on the clinical data from 28 PMBCL patients (altogether, 131 patients are followed-up) who were treated with R-DA-EPOCH ± radiotherapy at the NN Blokhin National Medical Cancer Research Center from 2011 to 2024. The median age was 35 years (range 21–48 years), most patients were women (n = 23; 82 %). This group of patients was selected because of the availability of PET-CT data to be closely analyzed prior to treatment, after 3 cycles (interim PET-CT), and by the end of the drug stage. This paper focuses on the data of 20 PMBCL patients including not only Deauville criteria (DC) for response but also the following technically determinable volumetric parameters: total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), as well as standardized uptake values (SUVmax, SUVpeak, ΔSUVmax, ΔSUVpeak, and rSUVmax), maximum diameter (Dmax and ΔDmax), and products of perpendicular lesion diameters (PD, ΔPD). RESULTS. With a 23-month median follow-up, the 2-year progression-free survival (PFS) in the total group was 78.6 % whereas the 2-year overall survival was 100 %. Incomplete metabolic response (DC 4–5) was reported in 19 (68 %) patients by the interim PET-CT and in 15 (54 %) patients by the end-of-treatment PET-CT. At the same time, the prognosis in patients with DC 4 and DC 5 was markedly different, but the 2-year PFS in the groups with complete (DC 1–3) and partial (DC 4) metabolic response appeared to be identical and accounted for 85 %. Moreover, all patients with DC 5 showed disease progression after chemotherapy. In PMBCL, two volumetric parameters (TMTV and TLG) have a particularly high prognostic value: the 2-year PFS in the group with high and low TMTV was 40 % and 93 %, respectively, and with high and low TLG it was 57 % and 92 %, respectively. CONCLUSION. PET-negative status (DC 1–3) confirmed already by the interim analysis is a reliable factor for favorable prognosis in PMBCL. After completing drug therapy, a considerable proportion of patients show incomplete metabolic response (DC 4–5). However, long-term survival rates corresponding to DC 4 are noninferior to those in patients with DC 1–3, whereas in patients with DC 5, they are considerably worse. High TMTV and TLG values prior to chemotherapy are associated with unfavorable course of the disease.

  • Open Access

    Options for Program Chemotherapy and Their Outcomes in Patients with Newly Diagnosed Mantle Cell Lymphoma Based on the Data from a Single Center

    by Ulyana Gordeevna Koshkina, G. S. Tumyan, A. A. Semenova, M. Yu. Kichigina, I. Z. Zavodnova, D. N. Tupitsyna, E. V. Paramonova, A. S. Antipova, V. O. Shpirko, Yu. I. Klyuchagina, et al.

    AIM. To assess the clinical characteristics and efficacy of chemotherapy for patients with newly diagnosed mantle cell lymphoma (MCL) based on the data from a single center. MATERIALS & METHODS. The study enrolled 60 MCL patients treated at the NN Blokhin National Medical Cancer Research Center from 2008 to 2024. The patients were 37–79 years of age (median 58 years); there were 22 women and 38 men. According to MIPI, there were 18 (30 %) low risk, 22 (37 %) intermediate risk, and 20 (33 %) high risk patients. Intensified regimens with high-dose cytarabine were administered to 31 (52 %) patients, whereas standard non-intensified R-CHOP, R-B, R-BAC and similar regimens were used in 29 (48 %) patients. Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 18 (30 %) patients after completing 6 cycles of induction immunochemotherapy. Maintenance rituximab therapy was assigned to 36 (60 %) patients. Ibrutinib, one of Bruton’s tyrosine kinase inhibitors, was added to basic immunochemotherapy in 11 (18 %) patients. RESULTS. The 3-year progression-free survival (PFS) of the recipients of intensified regimens with high-dose cytarabine was 73 % vs. 54 % (p < 0.05) shown by the recipients of the above listed standard non-intensified treatment protocols. The 3-year PFS of elderly recipients of bendamustine-based treatment was 64 % vs. 25 % shown by the patients treated with R-CHOP/R-CHOP-like regiments (p = 0.05). The 3-year PFS of recipients and non-recipients of maintenance rituximab therapy was 86 % and 33 %, respectively (p = 0.001). In the groups of recipients and non-recipients of auto-HSCT, it was reported to be 76 % and 56 % (p = 0.05). In the total group (n = 60), with the follow-up median of 36 months, the 3-year PFS was 64 % (median 54 months), and the 3-year OS was 80 % (median 84 months). The 3-year PFS rates in MCL patients varied considerably at different historic stages and were 42 % during the period from 2008 to 2017 and 86 % from 2018 to 2024 (p = 0.02). CONCLUSION. The present study covers the period of 16 years characterized by changing approaches to MCL treatment. The 3-year PFS rate of 86 % in the period of 2018–2024 increased nearly twofold compared to 2008–2017. Intensified program MCL first-line therapy with high-dose cytarabine significantly improves the long-term outcomes as opposed to standard immunochemotherapy (R-CHOP, R-B, etc.). For elderly MCL patients, bendamustine-based regimens appear to be most effective. Irrespective of patient’s age, it should be recognized that ibrutinib added to basic MCL chemotherapy holds the most promise. Maintenance rituximab therapy is a must in program treatment. Consolidation auto-HSCT performed after basic immunochemotherapy is associated with higher rates of long-term survival. The present study yielded results comparable to international data and showing a high reproducibility in real-world clinical practice.

  • Open Access

    Treatment of Patients with Relapsed/Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Own Data and Literature Review

    by Arman Vachakanovich Arakelyan, G. S. Tumyan, A. A. Semenova, M. Yu. Kichigina, I. Z. Zavodnova, D. N. Tupitsyna, E. V. Paramonova, A. S. Antipova, V. O. Shpirko, Yu. I. Klyuchagina, et al.

    AIM. To determine the optimal strategy of chemotherapy for patients with relapsed/refractory (r/r) primary mediastinal (thymic) large B-cell lymphoma (PMBCL). MATERIALS & METHODS. The study is based on the clinical data from 26 patients with r/r PMBCL treated at the NN Blokhin National Medical Cancer Research Center from 2010 to 2024. The patients were 20–48 years of age (median 33 years); there were 21 (81 %) women. All patients had a bulky mediastinal tumor mass (> 10 cm in maximum dimension). RESULTS. All calculations were performed in the combined group (n = 26) which included patients with both primary refractory PMBCL (n = 21) and tumor relapses (n = 5). Refractoriness was confirmed by PMBCL progressing within less than 6 months from the completion of the first therapy program. Relapses developed during 2 years after the first-line therapy. The treatment of r/r PMBCL included the R-DHAP, R-ICE, R-BeGeV, and R-B protocols. In 24 out of 26 patients, the second- or subsequent-line salvage therapy programs included immune checkpoint inhibitor (CPI; nivolumab or pembrolizumab) and immunoconjugate (brentuximab vedotin, BV) boosts. CPIs were received by 11 (42 %) patients, and CPI + BV were administered to 13 (50 %) patients. With the follow-up median of 28 months in the total group of r/r PMBCL patients (n = 26), the 3-year progression-free survival (PFS) was 41.7 % (median 14 months), whereas the 3-year overall survival (OS) was 73.7 % (median not reached). Radiotherapy (RT) was administered to 11 (42 %) patients. The RT recipients showed the 3-year PFS of 72.7 % and OS of 100 % as compared to non-recipients with 20.3 % and 56.3 %, respectively. Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 12 (46 %) patients. Auto-HSCT recipients showed the 3-year OS of 100 % as compared to non-recipients with 51 %. CONCLUSION. This study demonstrated that new drugs, in particular CPI ± BV, added to the second- and subsequent-line salvage therapy protocols in r/r PMBCL can be used to overcome the primary tumor refractoriness and neutralize this extremely unfavorable factor. High-dose chemotherapy (conditioning) with subsequent auto-HSCT is clearly associated with the best long-term survival rates. By the time of drafting this paper, 12 followed-up auto-HSCT recipients remained tumor-free. In cases of RT infeasibility at the initial stage, it was mediastinal radiation in the therapy for r/r PMBCL which showed its crucial prognostically favorable value and led to considerable improvement of PFS and OS rates. In general, the capacity of chemotherapy for patients with r/r PMBCL includes CPI ± BV-boosted salvage therapy protocols as well as added auto-HSCT and RT.


  • Open Access

    Diffuse Large B-Cell Lymphoma with High Risk of Central Nervous System Damage: A Literature Review, Prevention, Treatment, and Prognosis

    by Сельми Фаиковна Рамазанова, A. V. Arakelyan, A. A. Semenova, O. Yu. Baranova, D. N. Tupitsyna, M. Yu. Kichigina, I. Z. Zavodnova, E. V. Paramonova, A. S. Antipova, V. O. Shpirko, et al.

    AIM. To assess the feasibility of preventing the CNS damage in intermediate/high risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in accordance with CNS-IPI criteria. MATERIALS & METHODS. The trial was based on the clinical data from 60 patients with newly diagnosed DLBCL treated at the NN Blokhin National Medical Cancer Research Center from 2018 to 2024. The patients were 29–80 years of age (median 59 years); there were 34 women and 26 men. In accordance with the immunohistochemical algorithm of C.P. Hans, GCB subtype of DLBCL was identified in 18 (30 %) patients, non-GCB subtype was detected in 35 (58 %), and in 7 (12 %) patients subtype was not specified. By the time of primary DLBCL diagnosis, in 58 out of 60 patients tumor stage 4 was found, in 56 patients LDH increase was reported, and 22 patients showed ECOG ≥ 2. Extranodal lesions (> 1 zone) were identified in 53/60 patients. In accordance with the CNS-IPI score, with respect to CNS damage there were 22 (37 %) intermediate and 36 (60 %) high risk patients. In first-line therapy, R-CHOP (n = 40; 67 %) was most commonly used, R-DA-EPOCH (n = 10; 17 %) and Pola-R-CHP (n = 7; 11 %) were administered less often; 3 patients (5 %) received R-B. In 18 (30 %) patients, the initial lesions were treated with radiotherapy after completing drug chemotherapy. Different variants of CNS damage prevention in DLBCL included intrathecal (IT) administration of 3 drugs (methotrexate, cytarabine, and dexamethasone) and/or 2 methotrexate (МТХ) 3–3,5 g/m2 infusions. The trial identified two clinically comparable groups of DLBCL patients with CNS-IPI intermediate/high risk of CNS damage, who received chemotherapy throughout different periods of time (2018–2021 and 2022–2024). During the first period (n = 30), to prevent possible CNS damage, both methods were used as monotherapy or combined regimens consecutively. МТХ IT + МТХ HD (high dose) as prevention was administered to 20 (67 %) patients, 2 (7 %) patients received only МТХ HD, and 8 (26 %) patients received only МТХ IT. In the second group, CNS damage prevention was not provided for this category of DLBCL patients. RESULTS. In the total group (n = 60), with the follow-up median of 24 months, the 2-year progression-free survival (PFS) was 76 % (median 44 months), whereas the 2-year overall survival (OS) was 87 % (median 49 months). Age > 60 years was associated with the worst rate of the 2-year PFS (72 %) compared with patients ≤ 60 years (90 %) (p = 0.04). Besides, the 2-year OS in women was 77 % and 100 % in men, whereas in the groups of patients with ECOG ≥ 2 vs. < 2 it was 63 % and 95 %, respectively (p = 0.04). In patients with prevention of CNS damage, the 2-year PFS was 95 % vs. 64 % in patients without it (p = 0.001), and the 2-year OS in them was 95 % and 77 %, respectively (p = 0.05). In the course of this trial, the rate of DLBCL relapses with CNS involvement was 5 % (n = 3). Relapses were detected in 6, 18, and 46 months from the beginning of chemotherapy. CNS damage prevention was not performed in 3 patients with relapses. CONCLUSION. The data obtained in this ambispective trial support systemic and intrathecal use of methotrexate to increase the overall PFS rate and to reduce the relapse rate, also in CNS. The methods of CNS damage prevention are not associated with additional toxicity in DLBCL patients with intermediate/high CNS-IPI risk score.